Obesity and Metabolic Programming - Does It Really Start Before Birth?

Joana Menezes Nunes1*, Ana Cristina Santos2,3, José Luís Medina2 and Henrique Barros2,3

1Luz Saúde Private Hospitals, Portugal
2Faculty of Medicine, University of Porto, Portugal
3Institute of Public Health, University of Porto, Portugal

*Corresponding author: Joana Menezes Nunes, Luz Saúde Private Hospitals, Portugal
Submission: April 09, 2018; Published: April 13, 2018

Keywords: Obesity; Metabolism; Prenatal environment; Adiposity; Adipokines; Irisin

Introduction

Overweight and obesity are a growing epidemics and a major public health concern. This April 2018, the Endocrine Society has just published the new Scientific Statement about obesity management [1]. One of the biggest problems society struggles with obesity is the lack of awareness for this pathology, lots of times misunderstood and misclassified with aesthetics [1]. Actually, the social stigma is still far more important than the health consequences, namely cardio-metabolic disorders (e.g. atherosclerosis, dyslipidemia, arterial hypertension, type 2 diabetes mellitus, hyperuricemia), sleep apnea and other respiratory disease, fatty liver disease, cancer and osteoarticular diseases [1-4].

Despite the lack of reimbursement by politics and health insurers [1] and the limited therapeutic options for obesity treatment, the scientific community is making an effort to better understand obesity pathways and the pharmaceutical industry is working on novel drugs [5]. Obesity appears to be determined in utero [6]. A major mechanism that is being investigated is the perturbation of the off-spring’s DNA methylene, determined by both genetic and environmental influences [6-8]. Polygenic risk scores and neonatal methylation markers have been described and associated with birth weight and adiposity in early childhood [6-8].

Also, adipokines have been implicated in obesity pathogenesis. Leptin and adiponectin regulate metabolism and energy homeostasis in adults but it is still unclear their role in early life [9]. Leptin, the product of the obesity gene, informs the brain about body’s energy and nutrient status [10]. It is produced by adipocytes but is also found in placenta [11]. Recent studies have been reporting that higher leptin levels in cord blood are associated with fetal adiposity at birth [12,13]. However, there are still conflicting results about its lifespan relationship with obesity.

Some researchers report a week association with adiposity in late childhood and adolescence [13], others found a positive association between lower cord blood leptin levels and smaller size at birth but more pronounced weight gain in the first 6 months of life and higher BMI at 3 years of age [14] and others report that higher perinatal leptin levels were associated with lower 3-year adiposity and that higher age-3 leptin levels were associated with greater weight gain and adiposity by age-7 [15]. Adiponectin is solely secreted by adipocytes, has insulin-sensitizing effects and is reduced in obese adults and inversely related to leptin levels [16]. However, there is also a grey area about its role in fetal, neonatal and childhood obesity. Some studies suggest no relation to birth weight [12,13], others report a positive association with birth weight, an inverse association with weight gain in the first 6 months of life, and a positive relation with increased central adiposity at age 3 years-old [14].

On another hand, there is irisin, a myokine produced by the skeletal muscle after exercise and responsible for the ‘conversion’ of the white adipose tissue (an energy-saving organ) to brown adipose tissue (an energy-producing organ) [17]. New evidence suggests that irisin has a physiologic role in neonates, as irisin positively correlated with gestational age and birth weight Z-scores [18]. We believe that these conflicting results may be explained by other physiologic mechanisms of some other unknown metabolic regulators (such as irisin) and we advise that there is the need to use the same cohort from prenatal to adulthood, adjusting to environmental variables such as endocrine disruptors, to better understand the life span behavior of obesity and adiposity.

Obesity is a complex multi-factorial pathology determined in uterus and influenced by genetic, epigenetic and prenatal and
postnatal environment factors. All these recently discovered pathways are useful in identifying individuals at higher risk and implementing preventive medical strategies to reduce obesity and metabolic diseases later in life, as well as to develop new drugs that can actually intervene since birth.

References


